Regulatory MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority Pharmaceutical Business ReviewThe treatment targets adult patients with ES-SCLC who have experienced disease progression on or after platinum-based chemotherapy.RegulatoryOncologyRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) Pharmaceutical Business Review The treatment targets adult patients with ES-SCLC who have experienced disease progression on or after platinum-based chemotherapy. RegulatoryOncologyRead full story Post navigation Previous: Travere claims first FDA OK in rare kidney disease FSGSNext: Travere Therapeutics gains FDA approval for sparsentan in FSGS Related Stories Regulatory Third Circuit Affirms Denial of Stelara Biosimilar Injunction pharminent May 11, 2026 Regulatory Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher pharminent May 11, 2026 Regulatory BMS’ Sotyktu secures EC approval for psoriatic arthritis pharminent May 11, 2026
